New drug combo shows promise in controlling Hard-to-Treat cancers
NCT ID NCT02407509
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure how the drug behaves in the body. While not a cure, the study aims to help control these cancers by shrinking or slowing tumor growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW GRADE SEROUS OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guy's and St Thomas' Hospital
London, United Kingdom
-
Gynaecological Unit - Royal Marsden NHS Foundation Trust
London, United Kingdom
-
Royal Marsden NHS Foundation Trust
Sutton, Surrey, SM2 5PT, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a Tumor's DNA guide better cancer care for kids?